RS-5
/ Resolute Science
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
March 18, 2026
A novel TAM-targeted therapeutic for rare and aggressive solid tumors
(AACR 2026)
- "A complete response was observed in a doxorubicin-resistant soft tissue sarcoma (STS) PDX model. RS-5 exhibits a favorable PK/PD profile; MTD and DRF are complete, and 4-week toxicology studies are underway.These preclinical results support broad clinical utility, particularly for TAM-rich tumors. A first-in-human dose-escalation study is planned for the summer of 2026."
First-in-human • IO biomarker • Brain Cancer • Gastric Cancer • Glioma • Melanoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor
October 24, 2025
Resolute Science Receives FDA Orphan Drug Designation for its Lead Therapeutic, RS-5, for Soft Tissue Sarcomas
(PRWeb)
- "This regulatory milestone underscores RS-5's therapeutic potential and supports the company's continued progress toward initiating first-in-human clinical trials in 2026."
New trial • Orphan drug • Soft Tissue Sarcoma
1 to 2
Of
2
Go to page
1